Company: VEEAW
Filing Date: 2025-08-14
Form Type: 424B4
Source: 0001213900-25-076086
Chunk: 2

Company: VEEA INC.
Filing Date: 2025-08-14
Form: 424B4
Chunk 2
---
----|:------|-----------:|
| Public offering price                |     | $             | 1.00 |     | $     | 6,000,000– |
| Placement Agent fees(1)              |     | $             | 0.07 |     | $     |    420,000 |
| Proceeds, before expenses, to us (2) |     | $             | 0.93 |     | $     |  5,580,000 |

| (1) | We have agreed to pay the Placement Agent a cash fee equal to the sum of (i) 7.0% of the aggregate                                 
 gross proceeds raised in the offering by the investors introduced by the Placement Agent plus (ii) 3.5% of the aggregate gross     
 proceeds raised in the offering by the investors introduced by the Company, provided, however, that the Placement Agent shall      
 receive no cash fee for any payment made by NLabs in the form of the 2025 Related Party Notes (as defined below) for the shares of 
 common stock and common warrants sold in this offering in satisfaction of such indebtedness. We have also agreed to reimburse the  
 Placement Agent for certain of its offering-related expenses. See “Plan of Distribution” beginning on page 112 of                  
 this prospectus for a description of the compensation and expense reimbursement to be received by the Placement Agent.             |

| (2) | The amount of the proceeds to us presented in this table does not give 
 effect to any exercise of the common warrants.                         |

NLabs Inc., a Delaware corporation
(“NLabs”) an existing stockholder and an affiliate of the Company and the Company’s Chief Executive Officer,
holds certain of our outstanding non-convertible promissory notes in the aggregate principal amount of $3,176,000. The Company will satisfy
its obligation to repay the outstanding notes, plus accrued interest, of approximately $3,239,096, as of the date of this prospectus,
with the issuance of 3,239,096 shares of common stock with accompanying common warrants in this offering.

Upon NLabs’ acceptance
of securities in this offering as payment and satisfaction in full of the outstanding promissory notes, Allen Salmasi and NLabs would
beneficially own, in the aggregate, approximately 45.3% and 34.6% of our outstanding capital stock, respectively.

Delivery of the shares and common warrants is expected to be made on
or